A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.

GM-CSF-deficient mice are susceptible to pulmonary group B streptococcal infection. (1/2364)

Granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-targeted mice (GM-/-) cleared group B streptococcus (GBS) from the lungs more slowly than wild-type mice. Expression of GM-CSF in the respiratory epithelium of GM-/- mice improved bacterial clearance to levels greater than that in wild-type GM+/+ mice. Acute aerosolization of GM-CSF to GM+/+ mice significantly enhanced clearance of GBS at 24 hours. GBS infection was associated with increased neutrophilic infiltration in lungs of GM-/- mice, while macrophage infiltrates predominated in wild-type mice, suggesting an abnormality in macrophage clearance of bacteria in the absence of GM-CSF. While phagocytosis of GBS was unaltered, production of superoxide radicals and hydrogen peroxide was markedly deficient in macrophages from GM-/- mice. Lipid peroxidation, assessed by measuring the isoprostane 8-iso-PGF2alpha, was decreased in the lungs of GM-/- mice. GM-CSF plays an important role in GBS clearance in vivo, mediated in part by its role in enhancing superoxide and hydrogen peroxide production and bacterial killing by alveolar macrophages.  (+info)

Possible role for ligand binding of histidine 81 in the second transmembrane domain of the rat prostaglandin F2alpha receptor. (2/2364)

For the five principal prostanoids PGD2, PGE2, PGF2alpha, prostacyclin and thromboxane A2 eight receptors have been identified that belong to the family of G-protein-coupled receptors. They display an overall homology of merely 30%. However, single amino acids in the transmembrane domains such as an Arg in the seventh transmembrane domain are highly conserved. This Arg has been identified as part of the ligand binding pocket. It interacts with the carboxyl group of the prostanoid. The aim of the current study was to analyze the potential role in ligand binding of His-81 in the second transmembrane domain of the rat PGF2alpha receptor, which is conserved among all PGF2alpha receptors from different species. Molecular modeling suggested that this residue is located in close proximity to the ligand binding pocket Arg 291 in the 7th transmembrane domain. The His81 (H) was exchanged by site-directed mutagenesis to Gln (Q), Asp (D), Arg (R), Ala (A) and Gly (G). The receptor molecules were N-terminally extended by a Flag epitope for immunological detection. All mutant proteins were expressed at levels between 50% and 80% of the wild type construct. The H81Q and H81D receptor bound PGF2alpha with 2-fold and 25-fold lower affinity, respectively, than the wild type receptor. Membranes of cells expressing the H81R, H81A or H81G mutants did not bind significant amounts of PGF2alpha. Wild type receptor and H81Q showed a shallow pH optimum for PGF2alpha binding around pH 5.5 with almost no reduction of binding at higher pH. In contrast the H81D mutant bound PGF2alpha with a sharp optimum at pH 4.5, a pH at which the Asp side chain is partially undissociated and may serve as a hydrogen bond donor as do His and Gln at higher pH values. The data indicate that the His-81 in the second transmembrane domain of the PGF2alpha receptor in concert with Arg-291 in the seventh transmembrane domain may be involved in ligand binding, most likely not by ionic interaction with the prostaglandin's carboxyl group but rather as a hydrogen bond donor.  (+info)

Production of prostaglandin f2alpha and its metabolite by endometrium and yolk sac placenta in late gestation in the tammar wallaby, Macropus Eugenii. (3/2364)

In this study, we investigated production of prostaglandin (PG) F2alpha and its metabolite, PGFM, by uterine tissues from tammar wallabies in late pregnancy. Endometrial explants were prepared from gravid and nongravid uteri of tammars between Day 18 of gestation (primitive streak) and Day 26.5 (term) and were incubated in Ham's F-10 medium supplemented with glutamine and antibiotics for 20 h. PGF2alpha and PGFM in the medium were assayed by specific, validated RIAs. Control tissues (leg muscle) did not produce detectable amounts of either PG. Both gravid and nongravid endometria secreted PGF2alpha, and production increased significantly in both gravid and nongravid uteri towards term. PGFM was produced in small amounts by both gravid and nongravid uteri, and the rate of production did not increase. Neither oxytocin nor dexamethasone stimulated PG production in vitro in any tissue at any stage. Thus, the surge in peripheral plasma PGFM levels seen at parturition may arise from increased uterine PG production, but further study is needed to define what triggers this release.  (+info)

Down-regulation of oxytocin-induced cyclooxygenase-2 and prostaglandin F synthase expression by interferon-tau in bovine endometrial cells. (4/2364)

Oxytocin (OT) is responsible for the episodic release of luteolytic prostaglandin (PG) F2alpha from the uterus in ruminants. The attenuation of OT-stimulated uterine PGF2alpha secretion by interferon-tau (IFN-tau) is essential for prevention of luteolysis during pregnancy in cows. To better understand the mechanisms involved, the effect of recombinant bovine IFN-tau (rbIFN-tau) on OT-induced PG production and cyclooxygenase-2 (COX-2) and PGF synthase (PGFS) expression in cultured endometrial epithelial cells was investigated. Cells were obtained from cows at Days 1-3 of the estrous cycle and cultured to confluence in RPMI medium supplemented with 5% steroid-free fetal calf serum. The cells were then incubated in the presence or absence of either 100 ng/ml OT or OT+100 ng/ml rbIFN-tau for 3, 6, 12, and 24 h. OT significantly increased PGF2alpha and PGE2 secretion at all time points (p < 0.01), while rbIFN-tau inhibited the OT-induced PG production and reduced OT receptor binding in a time-dependent manner. OT increased the steady-state level of COX-2 mRNA, measured by Northern blot, which was maximal at 3 h (9-fold increase) and then decreased with time (p < 0.01). OT also caused an increase in COX-2 protein, which peaked at 12 h (11-fold increase), as measured by Western blot. Addition of rbIFN-tau suppressed the induction of COX-2 mRNA (89%, p < 0.01) and COX-2 protein (50%, p < 0.01) by OT. OT also increased PGFS mRNA, and this stimulation was attenuated by rbIFN-tau (p < 0.01). To ensure that the decrease in COX-2 was not solely due to down-regulation of the OT receptor, cells were stimulated with a phorbol ester (phorbol 12-myristate 13-acetate; PMA) in the presence and absence of rbIFN-tau. The results showed that rbIFN-tau also decreased PMA-stimulated PG production and COX-2 protein. It can be concluded that rbIFN-tau inhibition of OT-stimulated PG production is due to down-regulation of OT receptor, COX-2, and PGFS.  (+info)

Neurogenic vasodilatation of canine isolated small labial arteries. (5/2364)

Mechanisms underlying vasodilatation to nerve stimulation by electrical pulses and nicotine were analyzed in isolated canine small labial arteries. Transmural electrical stimulation (5 and 20 Hz) produced a contraction followed by a relaxation in labial arterial strips denuded of the endothelium, partially contracted with prostaglandin F2alpha. The contraction was abolished by prazosin or combined treatment with alpha, beta-methylene ATP. In the treated strips, neurogenic relaxation was abolished by NG-nitro-L-arginine (L-NA), a nitric oxide (NO) synthase inhibitor, and restored by L-arginine. The D-enantiomers were without effect. Nicotine (10(-4) M) also relaxed the arteries, in which the contractile response was abolished by prazosin and alpha, beta-methylene ATP. The relaxant response was attenuated but not abolished by L-NA; the inhibition was reversed by L-arginine. The remaining relaxation by nicotine was abolished by calcitonin gene-related peptide (CGRP)-[8 to 37], a CGRP1 receptor antagonist. Relaxations elicited by a lower concentration of nicotine (2 x 10(-5) M) sufficient to produce similar magnitudes of response to those induced by 5-Hz electrical nerve stimulation were also inhibited partially by L-NA. Histochemical study with the NADPH-diaphorase method demonstrated positively stained nerve fibers and bundles in the arterial wall, suggesting the presence of neuronal NO synthase. It is concluded that the relaxation induced by electrical nerve stimulation of small labial arteries is mediated exclusively by NO synthesized from L-arginine in nerve terminals, whereas nicotine in the concentrations used evokes relaxations by a mediation of nerve-derived NO and also CGRP, possibly from sensory nerves. The reason why nicotine but not electrical pulses stimulates sensory nerves and elicits vasorelaxation remains unsolved.  (+info)

Role of iNOS in the vasodilator responses induced by L-arginine in the middle cerebral artery from normotensive and hypertensive rats. (6/2364)

1. The substrate of nitric oxide synthase (NOS), L-arginine (L-Arg, 0.01 microM - 1 mM), induced endothelium-independent relaxations in segments of middle cerebral arteries (MCAs) from normotensive Wistar-Kyoto (WKY) and hypertensive rats (SHR) precontracted with prostaglandin F2alpha (PGF2alpha). These relaxations were higher in SHR than WKY arteries. 2. L-N(G)-nitroarginine methyl ester (L-NAME) and 2-amine-5,6-dihydro-6-methyl-4H-1,3-tiazine (AMT), unspecific and inducible NOS (iNOS) inhibitors, respectively, reduced those relaxations, specially in SHR. 3. Four- and seven-hours incubation with dexamethasone reduced the relaxations in MCAs from WKY and SHR, respectively. 4. Polymyxin B and calphostin C, protein kinase C (PKC) inhibitors, reduced the L-Arg-induced relaxation. 5. Lipopolysaccharide (LPS, 7 h incubation) unaltered and inhibited these relaxations in WKY and SHR segments, respectively. LPS antagonized the effect polymyxin B in WKY and potentiated L-Arg-induced relaxations in SHR in the presence of polymyxin B. 6. The contraction induced by PGF2alpha was greater in SHR than WKY arteries. This contraction was potentiated by dexamethasone and polymyxin B although the effect of polymyxin B was higher in SHR segments. LPS reduced that contraction and antagonized dexamethasone- and polymyxin B-induced potentiation, these effects being greater in arteries from SHR. 7. These results suggest that in MCAs: (1) the induction of iNOS participates in the L-Arg relaxation and modulates the contraction to PGF2alpha; (2) that induction is partially mediated by a PKC-dependent mechanism; and (3) the involvement of iNOS in such responses is greater in the hypertensive strain.  (+info)

Control of luteolysis in the one-humped camel (Camelus dromedarius). (7/2364)

Blood plasma concentrations of 13,14-dihydro-15-keto PGF2 alpha (PGFM) were measured in groups of mature non-pregnant and pregnant camels to study PGF2 alpha release patterns around the time of luteolysis and the timing of the signal for pregnancy recognition. Injection of each of four camels with 10 and 50 mg of PGF2 alpha showed clearly that five times the dose of exogenous hormone produced five times the amount of PGFM in peripheral plasma, thereby indicating that, as in other animal species, PGFM is the principal metabolite of PGF2 alpha in the camel. Serial sampling of three non-pregnant camels on each of days 8, 10 and 12, and three pregnant camels on day 10, after ovulation for 8 h showed a significant (P < 0.05) rise in mean plasma PGFM concentrations only on day 10 in the non-pregnant, but not the pregnant, animals. A single intravenous injection of 20, 50 or 100 iu oxytocin given to three groups of three non-pregnant camels on day 10 after ovulation did not increase their basal serum PGFM concentrations. However, daily treatment of six non-pregnant camels between days 6 and 15 (n = 3) or 20 (n = 3) after ovulation with 1-2 g of the prostaglandin synthetase inhibitor, meclofenamic acid, inhibited PGF2 alpha release and thereby resulted in continued progesterone secretion throughout the period of meclofenamic acid administration. These results showed that, as in other large domestic animal species, release of PGF2 alpha from, presumably, the endometrium controls luteolysis in the dromedary camel. Furthermore, reduction in the amount of PGF2 alpha released is associated with luteal maintenance and the embryonic signal for maternal recognition of pregnancy must be transmitted before day 10 after ovulation if luteostasis is to be achieved. However, the results also indicate that, in contrast to ruminants, the release of endometrial PGF2 alpha in the non-pregnant camel may not be controlled by the release of oxytocin.  (+info)

Effects of prostaglandin F2 alpha on intracellular pH, intracellular calcium, cell shortening and L-type calcium currents in rat myocytes. (8/2364)

OBJECTIVE: We have studied the mechanisms underlying the positive inotropic action of prostaglandin F2 alpha (PGF2 alpha) by monitoring intracellular calcium transients, intracellular pH, L-type calcium currents and cell shortening in isolated ventricular myocytes. METHODS: Rat myocytes were loaded with fura-2AM for intracellular calcium measurements, or BCECF-AM for pH measurements. Cell shortening was recorded using an edge detection system, and L-type calcium currents measured using whole cell patch clamping. RESULTS: PGF2 alpha (3 nmol l-1-3 mumol l-1 increased single myocyte shortening and reduced resting cell length in a concentration-dependent manner. While myocyte shortening was increased by PGF2 alpha, this was not associated with any change in the amplitude of intracellular calcium transients, diastolic calcium, or L-type calcium currents. However, the same myocytes were capable of responding to catecholamines with increases in calcium transient amplitude and L-type calcium currents. PGF2 alpha (3 mumol l-1 caused a reversible rise in intracellular pH of 0.08 +/- 0.01 pH units (n = 5, p < 0.05). The Na(+)-H+ exchanger inhibitor, HOE 694 (10 mumol l-1, abolished the PGF2 alpha-induced rise in pH and the increase in cell shortening. PGF2 alpha-induced increases in cell shortening and intracellular pH were also attenuated by the protein kinase C (PKC) inhibitor, chelerythrine (2 mumol l-1. CONCLUSION: The positive inotropic action of PGF2 alpha appears to be mediated via activation of the Na(+)-H+ exchanger with the possible involvement of PKC. This suggests that PGF2 alpha-produces intracellular alkalosis, which then sensitizes cardiac myofilaments to calcium.  (+info)

Dinoprost is a synthetic form of prostaglandin F2α, which is a naturally occurring hormone-like substance in the body. It is used in veterinary medicine as a uterotonic agent to induce labor and abortion in various animals such as cows and pigs. In human medicine, it may be used off-label for similar purposes, but its use must be under the close supervision of a healthcare provider due to potential side effects and risks.

It is important to note that Dinoprost is not approved by the FDA for use in humans, and its availability may vary depending on the country or region. Always consult with a licensed healthcare professional before using any medication, including Dinoprost.

More information is available on dinoprost including side effects, age restrictions, food interactions, whether the medicine is ... Active ingredient: dinoprost. The medicines below all contain the following active ingredient(s): dinoprost. You can select a ...
p,Dinoprost or Prostaglandin F,sub,2α,/sub, is used for termination of pregnancy and missed miscarriage, hydatidiform ... Dinoprost or Prostaglandin F2α is used for termination of pregnancy and missed miscarriage, hydatidiform mole, and intra- ...
Dinoprost tromethamine-Zhejiang Ausun Pharmaceutical Co., Ltd. ...
"LUTALYSE® Injection (dinoprost injection)". www.zoetisus.com. Retrieved 2021-04-06. "Hormonal Control of Estrus in Cattle - ...
Acute intermittent porphyria (AIP) is one of the porphyrias, a group of diseases involving defects in heme metabolism and that results in excessive secretion of porphyrins and porphyrin precursors. AIP manifests itself by abdomen pain, neuropathies, and constipation, but, unlike most types of porphyria, patients with AIP do not have a rash.
Dinoprost 7. Prostaglandin-Endoperoxide Synthases (Cyclooxygenase) 8. Alprostadil (Muse) 9. Leukotriene B4 ...
Medical management with 3 prostaglandin trials (dinoprost tromethamine; 2.5 to 5 mg, IM, q 12 to 24 h for 1 to 3 days) and ...
Acute intermittent porphyria (AIP) is one of the porphyrias, a group of diseases involving defects in heme metabolism and that results in excessive secretion of porphyrins and porphyrin precursors. AIP manifests itself by abdomen pain, neuropathies, and constipation, but, unlike most types of porphyria, patients with AIP do not have a rash.
Aktuelle API Auditberichte • GMP-Audits der Herstelung pharmazeutischer Ausgangs- und Wirkstoffe nach ICH Q7 / EU GMP Guide Part II • Diapharm
One day before the device was withdrawn; an injection of 25 mg of prostaglandin F2a (Dinoprost Pfizer, México) was administered ...
Why dont you want to use natural PGF2A (dinoprost) to induce parturition? ...
Dinitrophenol prostin f2 Lutalyse dinoprost PGF2 prostaglandin F2 Testabol Propionate Adderall Viagra Cialis OBH12 Dobetin Liv ...
https://www.watsonnoke.com/wp-content/uploads/2018/05/Structure-of-Dinoprost-Tromethamine-CAS-38562-01-5.png 134 376 WATSONNOKE ...
Eesti suurim valik veterinaarravimeid, täiendsöötasid ja farmitarvikuid. Üle 1500 toote. Abivalmis klienditugi. Kaup kätte kiirelt ja mugavalt.
Investigating the protective potential of dinoprost in a rat model of ischemia-reperfusion Savas Karakus, Mustafa Ozkaraca ...
Hereditary coproporphyria is one of the porphyrias, a group of diseases that involves defects in heme metabolism and that results in excessive secretion of porphyrins and porphyrin precursors. Inheritance is autosomal (usually autosomal dominant, but sometimes autosomal recessive).
Acute intermittent porphyria (AIP) is one of the porphyrias, a group of diseases involving defects in heme metabolism and that results in excessive secretion of porphyrins and porphyrin precursors. AIP manifests itself by abdomen pain, neuropathies, and constipation, but, unlike most types of porphyria, patients with AIP do not have a rash.
Dinoprost. A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its ... CloprostenolProstaglandins F, SyntheticProstaglandins, SyntheticLuteolytic AgentsProgesteroneDinoprostGonadotropins, Equine ... cloprostenol sodium or dinoprost tromethamine) for cattle, using the labeled dosage and administration instructions to cause ... SyntheticLuteolysisCorpus LuteumLuteolytic AgentsEstrus SynchronizationProgesteroneDinoprostEstrusLabor Stage, ThirdCallithrix ...
Dinoprost *6-Ketoprostaglandin F1 alpha *prostaglandins I *Epoprostenol *synthetic prostaglandins *synthetic prostaglandins + ...
Dive into the research topics of Diversity in cytokine response to bacteria associated with preterm birth by fetal membranes. Together they form a unique fingerprint. ...
Dive into the research topics of Effect of Interval from Melengestrol Acetate to Prostaglandin F2α on Timed and Synchronized Pregnancy Rates of Beef Heifers and Cows. Together they form a unique fingerprint. ...
San Hipólito-Luengo, Á., Alcaide, A., Ramos-González, M., Cercas, E., Vallejo, S., Romero, A., Talero, E., Sánchez-Ferrer, C. F., Motilva, V. & Peiró, C., 3 Oct 2017, In: Nutrition and Cancer. 69, 7, p. 1019-1027 9 p.. Research output: Contribution to journal › Article › peer-review ...
Dinoprost tromethamine. Dosage: 5ml intramuscular. 20 dose/ 100ml Vial ... 5 mg dinoprost per ml. Dinoprost tromethamine.\u003c\/li\u003e\n\u003cli\u003eDosage: 5ml intramuscular.\u003c\/li\u003e\n\ ... 5 mg dinoprost per ml. Dinoprost tromethamine.\u003c\/li\u003e\n\u003cli\u003eDosage: 5ml intramuscular.\u003c\/li\u003e\n\ ...
Dinoprost Tromethamine - - Add to cart. ✐. Diphenhydramine HCL USP - 147-24-0 Add to cart. ✐ ...
Guo, Y., Lanktree, M. B., Taylor, K. C., Hakonarson, H., Lange, L. A., Keating, B. J., Fairfax, B. P., Elbers, C. C., Barnard, J., Farrall, M., Padmanabhan, S., Baumert, J., Castillo, B. A., Gaunt, T. R., Gong, Y., Rajagopalan, R., Romaine, S. P. R., Kumari, M., Rafelt, S., Smith, E. N., & 178 othersLi, Y. R., Sivapalaratnam, S., van Iperen, E. P. A., Speliotes, E. K., Toskala, E., Zhang, L., Ochs-Balcom, H. M., Bhangale, T. R., Chandrupatla, H. R., Drenos, F., Gieger, C., Gupta, J., Johnson, T., Kleber, M. E., Makino, S., Mangino, M., Meng, Y., Nelson, C. P., Pankow, J. S., Pankratz, N., Price, T. S., Shaffer, J., Shen, H., Tischfield, S., Tomaszewski, M., Atwood, L. D., Bailey, K. M., Balasubramanyam, A., Baldwin, C. T., Basart, H., Bauer, F., Behr, E. R., Beitelshees, A. L., Berenson, G. S., Beresford, S. A. A., Bezzina, C. R., Bhatt, D. L., Boer, J. M. A., Braund, P. S., Burke, G. L., Burkley, B., Carty, C., Chen, W., Clarke, R., Cooper-DeHoff, R. M., Curtis, S. P., de Bakker, P. I. W., de ...
Tanaka, Y., Watanabe, T., Katsura, K., Tsujimoto, Y., Takai, T., Tanaka, T. S. T., Kawamura, K., Saito, H., Homma, K., Mairoua, S. G., Ahouanton, K., Ibrahim, A., Senthilkumar, K., Semwal, V. K., Matute, E. J. G., Corredor, E., El-Namaky, R., Manigbas, N., Quilang, E. J. P., Iwahashi, Y., & 3 othersNakajima, K., Takeuchi, E. & Saito, K., 2023, In: Plant Phenomics. 5, 0073.. Research output: Contribution to journal › Article › peer-review ...
... â ¼6-8 months of age by daily oral administration of 17.6 mg altrenogest for 13 days and 10 mg dinoprost IM on the last day of ...
Dinoprost intermediates 11. Indomethacin Intermediate 12. Eldecalcitol intermediate. 13. Voglibose intermediate. 14. ...
MeSH headings : Animals; Arachidonic Acid / metabolism; Cells, Cultured; Dinoprost / metabolism; Dinoprostone / metabolism; ...
  • Dinoprost tromethamine_Zhejiang Ausun Pharmaceutical Co., Ltd. (ausunpharm.com)
  • The nucleotide sequence of M-segment amplicons generated from your lung samples of five Dinoprost tromethamine seropositive deer mice displayed significant identity with SNV genotypes previously reported in Manitoba (Drebot et al. (ees2010prague.org)
  • Overall concentrations of SNV S-segment in three of four heart samples (DM 2, DM 26 and DM 51) tested were determined to be 500,000, 37,000, and 324,000 Dinoprost tromethamine copies/mg, respectively. (ees2010prague.org)
  • Although the presence of viral RNA does not necessarily forecast the presence of infectious disease, the Dinoprost tromethamine isolation of infectious SNV from your salivary gland of one animal lends support to the hypothesis that SNV replication happens in this cells and that SNV virions are shed in the saliva. (ees2010prague.org)
  • and another factor determined the administration of PGF2α: a) without PGF2α, b) administration of PGF2α in early postpartum (application of 25 mg of dinoprost at 28 days repeated 14 days later) or c) administration of PGF2α in late postpartum (application of 25 mg dinoprost at 42 days repeated 14 days later). (edu.pe)
  • n=23) was synchronized using two doses of PGF2α (25 mg of Dinoprost®) with a 12-day interval. (revista-agroproductividad.org)
  • Estrus was induced on both donor and recipient mares by intramuscular injection of 5 mg Dinoprost, aiming to obtain an ovulation interval of -1 to +3 between recipient and donor. (udea.edu.co)
  • Estrus was induced on both donor and recipient mares by intramuscular injection of 5 mg Dinoprost, aiming to obtain an ovulation interval of -1 to +3 between recipient and donor. (udea.edu.co)

No images available that match "dinoprost"